CL2021002651A1 - Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona - Google Patents

Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona

Info

Publication number
CL2021002651A1
CL2021002651A1 CL2021002651A CL2021002651A CL2021002651A1 CL 2021002651 A1 CL2021002651 A1 CL 2021002651A1 CL 2021002651 A CL2021002651 A CL 2021002651A CL 2021002651 A CL2021002651 A CL 2021002651A CL 2021002651 A1 CL2021002651 A1 CL 2021002651A1
Authority
CL
Chile
Prior art keywords
morpholinoazetidin
dioxopiperidin
isoindoline
hodgkin
dione
Prior art date
Application number
CL2021002651A
Other languages
English (en)
Inventor
Soraya Carrancio Anton Maria
J Buchholz Tonia
Lopez-Girona Antonia
Krishna Narla Rama
POURDEHNAD Michael
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2021002651A1 publication Critical patent/CL2021002651A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

Se proporcionan métodos de uso de 2- (2,6-DIOXOPIPERIDIN-3-YL) -4 - ((2-FLUORO-4 - ((3-MORFOLINOAZETIDIN-1-YL) METIL) BENCIL) AMINO) ISOINDOLINA- 1,3-DIONA, o un enantiómero, una mezcla de enantiomeros, un tautómero, un isotopólogo o una sal farmacéuticamente aceptable del mismo, solo o en combinacion con rituximab para tratar, prevenir o manejar el linfoma No Hodgkin.
CL2021002651A 2019-04-12 2021-10-08 Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona CL2021002651A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12

Publications (1)

Publication Number Publication Date
CL2021002651A1 true CL2021002651A1 (es) 2022-04-29

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002651A CL2021002651A1 (es) 2019-04-12 2021-10-08 Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona

Country Status (16)

Country Link
US (2) US11390617B2 (es)
EP (1) EP3952880A1 (es)
JP (1) JP2022527398A (es)
KR (1) KR20210151895A (es)
CN (1) CN114144182A (es)
AR (1) AR119715A1 (es)
AU (1) AU2020270917A1 (es)
BR (1) BR112021020372A2 (es)
CA (1) CA3132538A1 (es)
CL (1) CL2021002651A1 (es)
IL (1) IL287145A (es)
MA (1) MA55608A (es)
MX (1) MX2021012507A (es)
SG (1) SG11202111232RA (es)
TW (1) TW202103705A (es)
WO (1) WO2020210418A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020372334A1 (en) * 2019-10-21 2022-05-05 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
BR112022007386A2 (pt) * 2019-10-21 2022-07-05 Celgene Corp Métodos para tratar um câncer hematológico e o uso de biomarcadores companheiros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
JP2022552884A (ja) * 2019-10-21 2022-12-20 セルジーン コーポレーション （ｓ）－２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを含む医薬組成物およびその使用方法
EP4048279A1 (en) 2019-10-21 2022-08-31 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
KR20220103950A (ko) 2019-10-21 2022-07-25 셀진 코포레이션 (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온 및 그의 염을 포함하는 고체 형태, 및 그를 포함하는 조성물 및 그의 용도
BR112022007417A2 (pt) 2019-10-21 2022-07-12 Celgene Corp Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona
EP4313126A1 (en) * 2021-03-29 2024-02-07 Juno Therapeutics, Inc. Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
BR112023021015A2 (pt) * 2021-04-21 2023-12-19 Bristol Myers Squibb Co Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona
IL305490A (en) * 2021-04-21 2023-10-01 Celgene Corp Treatment methods for B-Cell lymphoma using combination therapy
IL307942A (en) 2021-06-21 2023-12-01 Celgene Corp Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline -1, 3-dione

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58523B1 (sr) * 2010-02-11 2019-04-30 Celgene Corp Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
US20140221427A1 (en) * 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
CN108245518B (zh) * 2012-08-09 2021-08-31 细胞基因公司 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6- 二酮治疗癌症的方法
JP6469077B2 (ja) * 2013-04-02 2019-02-13 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソ−ピペリジン３−イル）−イソインドリン−１，３−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
PT3643709T (pt) * 2014-10-30 2021-12-20 Kangpu Biopharmaceuticals Ltd Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
LT3784663T (lt) * 2018-04-23 2023-10-25 Celgene Corporation Pakeistieji 4-aminoizoindolin-1,3-diono junginiai ir jų naudojimas limfomos gydymui

Also Published As

Publication number Publication date
KR20210151895A (ko) 2021-12-14
EP3952880A1 (en) 2022-02-16
CN114144182A (zh) 2022-03-04
MX2021012507A (es) 2022-01-24
IL287145A (en) 2021-12-01
US20200325129A1 (en) 2020-10-15
AR119715A1 (es) 2022-01-05
CA3132538A1 (en) 2020-10-15
WO2020210418A1 (en) 2020-10-15
MA55608A (fr) 2022-02-16
SG11202111232RA (en) 2021-11-29
AU2020270917A1 (en) 2021-11-04
TW202103705A (zh) 2021-02-01
JP2022527398A (ja) 2022-06-01
US20220324855A1 (en) 2022-10-13
BR112021020372A2 (pt) 2021-12-07
US11390617B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
CL2021002651A1 (es) Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
RS54928B1 (sr) Poboljšano lečenje multiplog mijeloma
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20081894A1 (es) Derivados de isoindolina 4'-o-sustituidos y composiciones que los comprenden y metodos para usarlos
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
AR058892A1 (es) Metodos para tratar lupus cutaneo con el uso de compuestos de aminoisoindolina
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
PH12020552088A1 (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
CR8146A (es) Metodos para tratar canceres usando formas poliformicas de 3-(4-amino -1-oxo-1,3 dihidro-isoindol-2-il)- piperidina-2,6-dione
MX2007005205A (es) Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
CL2018001830A1 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
CO2021007691A2 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
BR112017012646A2 (pt) Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
BR112019004639A2 (pt) formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
SG11201901617PA (en) Azole compound ophthalmic preparation
AR125390A1 (es) Métodos de tratamiento del linfoma no hodgkin con 2-(2,6-dioxopiperidin-3-il)-4-((2-lfuoro-4-((3-morfolinoazetidin-1-il) metil)benzil)amino)isoindoline-1,3-diona
BR112022007150A2 (pt) Métodos de tratamento de leucemia linfocítica crônica usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
BR112022007417A2 (pt) Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona